<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/CB597297-71EC-49CA-868E-47371DFC4207"><gtr:id>CB597297-71EC-49CA-868E-47371DFC4207</gtr:id><gtr:name>Oxford Radcliffe Hospitals NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Medical Sciences Division</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/CB597297-71EC-49CA-868E-47371DFC4207"><gtr:id>CB597297-71EC-49CA-868E-47371DFC4207</gtr:id><gtr:name>Oxford Radcliffe Hospitals NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F1D1CEC4-C1D4-4B6C-9629-E4522EFDA6E2"><gtr:id>F1D1CEC4-C1D4-4B6C-9629-E4522EFDA6E2</gtr:id><gtr:firstName>Sten</gtr:firstName><gtr:otherNames>Eirik</gtr:otherNames><gtr:surname>Jacobsen</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0801073"><gtr:id>599C728E-8029-4D23-B23F-5658C4B62011</gtr:id><gtr:title>Delineating the cellular and molecular pathways of hematopoietic stem cell fate decisions</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801073</gtr:grantReference><gtr:abstractText>The understanding of cell differentiation is of critical importance for the development of modern medicine to allow for efficient use of cell-based therapies, and to specifically identify drug targets that can enhance regeneration of required cell types, and also selectively target and kill transformed malignant cells. Integrity of the blood system depends on a large number of essential blood cell types being continuously replenished from a rare population of blood forming stem cells, representing a paradigm for how diversity can be achieved from a common stem cell through alternative cell fates. Bone marrow transplantation and the use of several blood cell growth factors have over the last decades translated basic knowledge about blood forming stem cells into efficient cell replacement therapies. However, bone marrow transplantation is still associated with substantial treatment related mortality, and to address this more knowledge is needed with regard to the identity of stem cell types in the bone marrow responsible for regeneration of different blood cell lineages, and how these are regulated. Furthermore, as normal stem cells and their immediate progeny are thought to frequently be the origin of cancer stem cells, and since such transformation frequently occurs through mutations in pathways regulating normal stem cells and blood cell development, it is equally clear that a better understanding of normal blood cell development, will facilitate development of more efficient therapies to eradicate leukaemic stem cells. In the herein proposed studies, a number of novel strategies will be developed to identify and characterise, in mouse as well as man, key intermediates in the development from stem cells to mature blood cells, as well as the key regulators of these transitions from stem cells to specific blood cell lineages. Furthermore, we will translate knowledge regarding the role of key blood cell growth factors in regulation of the immune system in mice to man, through new studies in immunodeficient patients which have mutations resulting in loss of function of the same growth factor pathways.</gtr:abstractText><gtr:technicalSummary>The intergrity of the haematopoietic system depends on a large number of blood cell lineages being continuously replaced from a rare population of self renewing haematopoietic stem cells (HSCs), representing a paradigm for how multilineage diversity can be achieved from a common stem cell through lineage commitment and subsequent differentiation. Although the haematopoietic system is purported to be the best understood organ system, many questions of fundamental importance remain to be resolved, in particular with regard to early lineage development and commitment decisions, at the cellular and molecular levels. Further, the knowledge obtained so far has largely been derived from studies in mice (or more primitive model organisms), and although of considerable relevance, there is a need to translate this to man, in particular as there are indications of key regulators in mice playing little or quite different roles in man. Herein, we propose three lines of investigations to significantly improve the understanding of the cellular pathways of lymphoid lineage development and commitment and its regulation in the haematopoietic system. The specific aims are to: 1) Further establish and characterise the cellular pathways governing lymphoid lineage fate from HSCs, including studies of human stem and progenitor cells, applying novel reporter systems 2) Investigate the roles of GATA-3 and the Notch pathway in restricting multipotent haematopoietic progenitors towards a T cell fate; and 3) Establish the role of key cytokine receptors and their ligands in early stages of human lymphopoiesis. To make significant progress beyond what is already ?state of the art?, we have developed a number of new tools and strategies to dissect the cellular pathways by which HSCs undergo lymphoid lineage restriction and the molecular regulation of this process. These include novel mouse reporter lines and human reporters for fate mapping and stem and progenitor cell identification and characterisation, a system for tracking the fates of single HSCs and multipotent progenitors undergoing cell divisions, and application of inducible lack and gain of function models to establish the role of GATA-3 and Notch in lymphoid commitment and development. Finally, we will try to translate knowledge regarding the role of key cytokine receptors and ligands in regulation of early lymphoid development in mice to man, through new studies in patients with lack of function mutations in some of these receptors, and by screening for additional and novel mutations.</gtr:technicalSummary><gtr:fund><gtr:end>2015-09-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2536416</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lund University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Geissmann F.</gtr:description><gtr:id>6FFF97AB-09EC-4A68-90C6-56ED3B73B717</gtr:id><gtr:impact>-</gtr:impact><gtr:partnerContribution>-</gtr:partnerContribution><gtr:piContribution>-</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oxford Radcliffe Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Weatherall Institute of Molecular Medicine (WIMM)</gtr:department><gtr:description>Claus Nerlov</gtr:description><gtr:id>AA559359-8873-447F-BD52-14DFC1D82F3C</gtr:id><gtr:impact>As listed in outcome multiple high impact joint publications</gtr:impact><gtr:partnerContribution>Mouse genetic models of normal and malignant hematopoiesis</gtr:partnerContribution><gtr:piContribution>stem and progenitor cell characterisation</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oxford Radcliffe Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Weatherall Institute of Molecular Medicine (WIMM)</gtr:department><gtr:description>Marella de Bruijn</gtr:description><gtr:id>E7215B18-C873-46A3-A82D-7D3DBB249944</gtr:id><gtr:impact>Several publications, including Boiers et al, Cell Stem Cell 2013 and Luc et al, Nature Immunology 2012</gtr:impact><gtr:partnerContribution>Expertise in mouse developmental hematopoiesis</gtr:partnerContribution><gtr:piContribution>Mouse Models for stem and progenitor biology</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Sten Linnarsson</gtr:description><gtr:id>316D45A6-56B3-4F85-A632-904F0D577FCC</gtr:id><gtr:impact>Publications as listed above</gtr:impact><gtr:partnerContribution>Sten Linnarsson is a world leader in single cell RNA sequencing and his input has been key to several of our reported publications utilising small cell number or single cell RNA sequencing (Cell Stem Cell 2013; Cancer Cell 2014)</gtr:partnerContribution><gtr:piContribution>Single cell analysis of stem and progenitor cells</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cambridge Institute for Medical Research (CIMR)</gtr:department><gtr:description>Anthony (Tony) Green</gtr:description><gtr:id>3686279A-B779-4574-9723-37EDF58575AB</gtr:id><gtr:impact>-</gtr:impact><gtr:partnerContribution>-</gtr:partnerContribution><gtr:piContribution>-</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lund University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Rickard Sandberg</gtr:description><gtr:id>07B61D70-5405-488D-A734-C156349C4C5D</gtr:id><gtr:impact>-</gtr:impact><gtr:partnerContribution>-</gtr:partnerContribution><gtr:piContribution>-</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oxford Radcliffe Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Weatherall Institute of Molecular Medicine (WIMM)</gtr:department><gtr:description>Adam Mead</gtr:description><gtr:id>E8EF64A1-B374-499A-9EE3-45107BCB7A03</gtr:id><gtr:impact>Multiple publications listed in outcome</gtr:impact><gtr:partnerContribution>Molecular analysis of hematopoiesis</gtr:partnerContribution><gtr:piContribution>Mouse models of normal and malignant hematopoiesis</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>The John Fell Fund</gtr:department><gtr:description>Acquisition of high-end FACS cell sorter for WIMM FACS facility.</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>1D5ED488-4E65-404C-8941-40EB4CBD9E53</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>93000000</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>SEK</gtr:currCode><gtr:currCountryCode>Sweden</gtr:currCountryCode><gtr:currLang>sv_SE</gtr:currLang><gtr:description>Establishment of Hematopoietic Stem Cell Research Program at the Karolinska Institute</gtr:description><gtr:fundingOrg>Swedish Research Council</gtr:fundingOrg><gtr:id>C5E065AE-C011-4895-863A-C694E937CD59</gtr:id><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2766300</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Programme Grant</gtr:department><gtr:description>Regulation of normal hematopoiesis</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>435B8610-8804-4237-89B4-D9410314C378</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>two PhD fellowships</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Marie Curie Actions</gtr:fundingOrg><gtr:id>B53EE868-83AB-49E8-89AE-0A713679363C</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000000</gtr:amountPounds><gtr:country>Sweden, Kingdom of</gtr:country><gtr:currCode>SEK</gtr:currCode><gtr:currCountryCode>Sweden</gtr:currCountryCode><gtr:currLang>sv_SE</gtr:currLang><gtr:description>Professor/ Prize in Medicine 2015</gtr:description><gtr:end>2025-12-02</gtr:end><gtr:fundingOrg>Torsten S?derbergs Stiftelse</gtr:fundingOrg><gtr:id>9B711D64-F59E-435F-A448-BCD018BC99CA</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Molecular Haematology Unit</gtr:department><gtr:description>Characterisation and regulation of distinct hematopoietic stem and progenitor cells</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>745AD179-91E1-4516-B52E-A866B444F6A5</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>270000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical PhD programme</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>508A1749-B3E9-47F2-BB35-908F110CDEC0</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Chairman of Committee for allogeneic transplantations and cell therapies, Karolinska University Hospital</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E0985C26-2A76-4A60-B788-D3F82363AD0D</gtr:id><gtr:impact>Allogeneic transplantations and cell therapies.</gtr:impact><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of Board of Center for Molecular Medicine, Karolinska Institutet</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A2E2CD30-B677-4C83-BDCB-CD62FF2A2DE0</gtr:id><gtr:impact>Member of Board of Center for Molecular Medicine, Karolinska Institutet</gtr:impact><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>International Society for Stem Cell Research (ISSCR) McEwen Award for Innovation selection committee</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>61ED6151-CDD9-47FC-8383-1AE950263564</gtr:id><gtr:impact>International Society for Stem Cell Research (ISSCR) McEwen Award for Innovation selection committee</gtr:impact><gtr:type>Membership of a guideline committee</gtr:type><gtr:url>http://www.isscr.org</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of Scientific Advisory Board, Stem Cell Institute, Leuven, Belgium</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>78C0EA85-3CB8-41A9-8442-F0A36E8E0B13</gtr:id><gtr:impact>Member of Scientific Advisory Board, Stem Cell Institute, Leuven, Belgium (Director Professor Catherine Verfaillie) - Starting date 2005-date</gtr:impact><gtr:type>Participation in a advisory committee</gtr:type><gtr:url>http://www.kuleuven.be/samenwerking/scil</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of Board of Center of Excellence in Developmental Biology, Karolinska Institute</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>754BC727-071B-47C1-A35D-9BEA4B1598E3</gtr:id><gtr:impact>Member of Board of Center of Excellence in Developmental Biology, Karolinska Institute (Director, Professor Urban Lendahl)</gtr:impact><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>OX Stem Oncology</gtr:companyName><gtr:description>Establishment (as co-founder) of a spin-off company for development of targeting of cancer stem cells.</gtr:description><gtr:id>F9BD62E7-E5CA-4632-8546-9A02D59F3C83</gtr:id><gtr:impact>Development of therapeutic targeting of cancer stem cells.</gtr:impact><gtr:yearCompanyFormed>2016</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4992351E-035F-4254-ACDF-827E718FA8DB"><gtr:id>4992351E-035F-4254-ACDF-827E718FA8DB</gtr:id><gtr:title>Initial seeding of the embryonic thymus by immune-restricted lympho-myeloid progenitors.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6bc2a33653d404809acfd047a1a3aa3c"><gtr:id>6bc2a33653d404809acfd047a1a3aa3c</gtr:id><gtr:otherNames>Luis TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/00B08209-122E-4211-A7C1-9EC8784DB1CE"><gtr:id>00B08209-122E-4211-A7C1-9EC8784DB1CE</gtr:id><gtr:title>Germline counterparts of oncogenic mutations: who gives a JAK?.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5fb12a98d4056670ebefede87ebda6ba"><gtr:id>5fb12a98d4056670ebefede87ebda6ba</gtr:id><gtr:otherNames>Mead AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B0DD8A7A-AF7B-471B-A20D-02186F9BCD0E"><gtr:id>B0DD8A7A-AF7B-471B-A20D-02186F9BCD0E</gtr:id><gtr:title>Dicer is selectively important for the earliest stages of erythroid development.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/867a455fe097c2dfa583641b7668df6a"><gtr:id>867a455fe097c2dfa583641b7668df6a</gtr:id><gtr:otherNames>Buza-Vidas N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DA768909-E9D3-4D70-84B3-8D16C007AB52"><gtr:id>DA768909-E9D3-4D70-84B3-8D16C007AB52</gtr:id><gtr:title>Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d7c907488f14fd30f5bc6cabdea40dc8"><gtr:id>d7c907488f14fd30f5bc6cabdea40dc8</gtr:id><gtr:otherNames>Bardini M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0FC0EB5C-B612-48C8-A956-EC9976FB0FF7"><gtr:id>0FC0EB5C-B612-48C8-A956-EC9976FB0FF7</gtr:id><gtr:title>A dynamic niche provides Kit ligand in a stage-specific manner to the earliest thymocyte progenitors.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5e241df9506cc57c225f4d67f9f5101c"><gtr:id>5e241df9506cc57c225f4d67f9f5101c</gtr:id><gtr:otherNames>Buono M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9F9D0DAE-71AC-43C3-A262-2FA6C8FA0FCE"><gtr:id>9F9D0DAE-71AC-43C3-A262-2FA6C8FA0FCE</gtr:id><gtr:title>FLT3 expression initiates in fully multipotent mouse hematopoietic progenitor cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/867a455fe097c2dfa583641b7668df6a"><gtr:id>867a455fe097c2dfa583641b7668df6a</gtr:id><gtr:otherNames>Buza-Vidas N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DF177558-EA46-4446-9BEC-EF2EBDBA3046"><gtr:id>DF177558-EA46-4446-9BEC-EF2EBDBA3046</gtr:id><gtr:title>Lymphomyeloid contribution of an immune-restricted progenitor emerging prior to definitive hematopoietic stem cells.</gtr:title><gtr:parentPublicationTitle>Cell stem cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d5020f1fc79f56da95e57541d9bb5da4"><gtr:id>d5020f1fc79f56da95e57541d9bb5da4</gtr:id><gtr:otherNames>B?iers C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1875-9777</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/20258EF6-733E-47AA-AD7C-227192E13F6E"><gtr:id>20258EF6-733E-47AA-AD7C-227192E13F6E</gtr:id><gtr:title>Primitive Embryonic Macrophages are Required for Coronary Development and Maturation.</gtr:title><gtr:parentPublicationTitle>Circulation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a745ead6e86499980d0b10512f52e0cb"><gtr:id>a745ead6e86499980d0b10512f52e0cb</gtr:id><gtr:otherNames>Leid J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0009-7330</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B3065CD0-9E7A-4ABB-8261-689C530E015F"><gtr:id>B3065CD0-9E7A-4ABB-8261-689C530E015F</gtr:id><gtr:title>GATA3 is redundant for maintenance and self-renewal of hematopoietic stem cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/867a455fe097c2dfa583641b7668df6a"><gtr:id>867a455fe097c2dfa583641b7668df6a</gtr:id><gtr:otherNames>Buza-Vidas N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3474B00E-5068-46DC-88D1-2A1C754DE66F"><gtr:id>3474B00E-5068-46DC-88D1-2A1C754DE66F</gtr:id><gtr:title>A lineage of myeloid cells independent of Myb and hematopoietic stem cells.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6611fb1d82a723ab6d7bd458727956ee"><gtr:id>6611fb1d82a723ab6d7bd458727956ee</gtr:id><gtr:otherNames>Schulz C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/91F3C391-3FE9-4987-8065-DCCA87A78EB9"><gtr:id>91F3C391-3FE9-4987-8065-DCCA87A78EB9</gtr:id><gtr:title>Distinct myeloid progenitor-differentiation pathways identified through single-cell RNA sequencing.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5c898c712828706075492c628cb10fce"><gtr:id>5c898c712828706075492c628cb10fce</gtr:id><gtr:otherNames>Drissen R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2B59E755-FD6E-4F6E-8AEC-CB73479F231B"><gtr:id>2B59E755-FD6E-4F6E-8AEC-CB73479F231B</gtr:id><gtr:title>Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c678f61d9baba78039fd689d1985a666"><gtr:id>c678f61d9baba78039fd689d1985a666</gtr:id><gtr:otherNames>Woll PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/40B5D9BE-2A90-45EC-B2D3-67719E265B10"><gtr:id>40B5D9BE-2A90-45EC-B2D3-67719E265B10</gtr:id><gtr:title>FLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitors.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5fb12a98d4056670ebefede87ebda6ba"><gtr:id>5fb12a98d4056670ebefede87ebda6ba</gtr:id><gtr:otherNames>Mead AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DB5E0B86-29A3-4195-9F16-DC14A510C9DC"><gtr:id>DB5E0B86-29A3-4195-9F16-DC14A510C9DC</gtr:id><gtr:title>Erythropoietin guides multipotent hematopoietic progenitor cells toward an erythroid fate.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/884a8401cd72205f42779a840d6a93a3"><gtr:id>884a8401cd72205f42779a840d6a93a3</gtr:id><gtr:otherNames>Grover A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ECBD95E4-A65E-4DFC-B305-7AB962C67CA2"><gtr:id>ECBD95E4-A65E-4DFC-B305-7AB962C67CA2</gtr:id><gtr:title>Tumor necrosis factor restricts hematopoietic stem cell activity in mice: involvement of two distinct receptors.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/12afb9b38ce2e9ee422a58cd5a8fe34d"><gtr:id>12afb9b38ce2e9ee422a58cd5a8fe34d</gtr:id><gtr:otherNames>Pronk CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1E52EBD6-9AFA-47F9-A080-CB2CAEDF2D64"><gtr:id>1E52EBD6-9AFA-47F9-A080-CB2CAEDF2D64</gtr:id><gtr:title>Transcriptional repression of Gata3 is essential for early B cell commitment.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/384b11b2c521a3ead015d219baa5bdbc"><gtr:id>384b11b2c521a3ead015d219baa5bdbc</gtr:id><gtr:otherNames>Banerjee A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/86B2034D-732C-439D-8E74-5C4BC226CD8D"><gtr:id>86B2034D-732C-439D-8E74-5C4BC226CD8D</gtr:id><gtr:title>The earliest thymic T cell progenitors sustain B cell and myeloid lineage potential.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/863c8044fc8bc8103f03fb2384b7e08c"><gtr:id>863c8044fc8bc8103f03fb2384b7e08c</gtr:id><gtr:otherNames>Luc S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FC95BA8D-522C-4674-9B8F-A3A3BF07B9D6"><gtr:id>FC95BA8D-522C-4674-9B8F-A3A3BF07B9D6</gtr:id><gtr:title>Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9dcbcbb174ef85060f893c5185d2dbd0"><gtr:id>9dcbcbb174ef85060f893c5185d2dbd0</gtr:id><gtr:otherNames>Sanjuan-Pla A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DD16D3CA-C7C3-429F-9D35-B25CE9D35FAC"><gtr:id>DD16D3CA-C7C3-429F-9D35-B25CE9D35FAC</gtr:id><gtr:title>Single-cell RNA sequencing reveals molecular and functional platelet bias of aged haematopoietic stem cells.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/884a8401cd72205f42779a840d6a93a3"><gtr:id>884a8401cd72205f42779a840d6a93a3</gtr:id><gtr:otherNames>Grover A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A46BEB4E-6A4E-4B37-96DE-688E2A81EBC7"><gtr:id>A46BEB4E-6A4E-4B37-96DE-688E2A81EBC7</gtr:id><gtr:title>Macrophage colony-stimulating factor receptor marks and regulates a fetal myeloid-primed B-cell progenitor in mice.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/77b898934872e74bda9b511e73d71ee7"><gtr:id>77b898934872e74bda9b511e73d71ee7</gtr:id><gtr:otherNames>Zriwil A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CA728A33-E66F-41FF-8CC9-94F48C06CA58"><gtr:id>CA728A33-E66F-41FF-8CC9-94F48C06CA58</gtr:id><gtr:title>Expression and role of FLT3 in regulation of the earliest stage of normal granulocyte-monocyte progenitor development.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d5020f1fc79f56da95e57541d9bb5da4"><gtr:id>d5020f1fc79f56da95e57541d9bb5da4</gtr:id><gtr:otherNames>B?iers C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/02D13847-A6E5-4FC9-8C0C-E48E994A5F60"><gtr:id>02D13847-A6E5-4FC9-8C0C-E48E994A5F60</gtr:id><gtr:title>Impact of isolated germline JAK2V617I mutation on human hematopoiesis.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5fb12a98d4056670ebefede87ebda6ba"><gtr:id>5fb12a98d4056670ebefede87ebda6ba</gtr:id><gtr:otherNames>Mead AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801073</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>